The article "Obesity-related asthma and its relationship with microbiota" by Jinli Huang et al. explores the complex interplay between obesity and asthma, highlighting the mechanisms and clinical implications of this relationship. Obesity is a significant risk factor for asthma, with studies showing that obesity precedes asthma attacks and increases the severity of asthma in both adults and children. The authors discuss the clinical features of obesity-related asthma, including increased symptoms, poor quality of life, and higher hospitalization rates. They also delve into the pathogenesis of obesity-related asthma, emphasizing the role of inflammation, mechanical effects, and metabolic disorders. The gut microbiota is identified as a critical factor, with obesity leading to gut microbiota dysbiosis, reduced bacterial diversity, and increased inflammation. This dysbiosis can affect immune responses, lung function, and airway hyperresponsiveness. The article also reviews current treatment options, noting that standard asthma treatments are less effective in obese patients due to factors such as reduced drug bioavailability and increased inflammation. Finally, the authors suggest that targeted therapies, including microRNAs, TLR antagonists, and biologics, may offer promising interventions for managing obesity-related asthma.The article "Obesity-related asthma and its relationship with microbiota" by Jinli Huang et al. explores the complex interplay between obesity and asthma, highlighting the mechanisms and clinical implications of this relationship. Obesity is a significant risk factor for asthma, with studies showing that obesity precedes asthma attacks and increases the severity of asthma in both adults and children. The authors discuss the clinical features of obesity-related asthma, including increased symptoms, poor quality of life, and higher hospitalization rates. They also delve into the pathogenesis of obesity-related asthma, emphasizing the role of inflammation, mechanical effects, and metabolic disorders. The gut microbiota is identified as a critical factor, with obesity leading to gut microbiota dysbiosis, reduced bacterial diversity, and increased inflammation. This dysbiosis can affect immune responses, lung function, and airway hyperresponsiveness. The article also reviews current treatment options, noting that standard asthma treatments are less effective in obese patients due to factors such as reduced drug bioavailability and increased inflammation. Finally, the authors suggest that targeted therapies, including microRNAs, TLR antagonists, and biologics, may offer promising interventions for managing obesity-related asthma.